Tag: Lord Freyberg

The below Parliamentary question was asked by Lord Freyberg on 2016-01-13.

To ask Her Majesty’s Government what molecular testing takes place in the UK in mesothelioma and other rare cancers; and how that compares to more common cancers such as breast, lung or colorectal cancer.

Lord Prior of Brampton

The UK Genetic Testing Network evaluates new genetic tests and aims to promote equity of access to genetic testing in the National Health Service. Genetic testing is not performed routinely in cases of mesothelioma and there is currently no approved genetic test for patients with mesothelioma.

In September 2015, the Department confirmed a commitment from NHS England to implement the independent Cancer Taskforce’s recommendations on molecular diagnostics. This will mean that around 25,000 additional people a year will have their cancers genetically tested to identify the most effective treatments.

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 4 February (HL5344) and on 11 February (HL5970), how many of the 8,000 expected clinical reports are in the cancer part of that project, as compared to the rare disease; and in the cancer part of that project, how many are planned for delivery by the end of (1) March, (2) June, and (3) September.

Lord Prior of Brampton

The 100,000 Genomes project cancer pipeline is still being evaluated and the precise proportion of the reports that will relate to cancer is not currently known.

The below Parliamentary question was asked by Lord Freyberg on 2016-06-13.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 11 February (HL5970), how many of the 8,000 planned reports in 2016 will come from (1) the rare disease programme, and (2) the cancer programme.

Lord Prior of Brampton

At this stage, Genomics England cannot provide an exact breakdown of the 8,000 planned reports. This will depend on the participants that NHS Genomic Medicine Centres recruit.

The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.

To ask Her Majesty’s Government what measures they intend to put in place to ensure that patients with radioiodine refractory differentiated thyroid cancer can receive all effective clinical treatments currently available through EU authorisation.

Lord Prior of Brampton

Changes to the process for evaluating cancer drugs were introduced at the end of July 2016 as part of the new arrangements for the Cancer Drugs Fund (CDF). Under the new arrangements, all new cancer drugs are expected to be referred to the National Institute for Health and Care Excellence (NICE) for evaluation through its technology appraisal programme. In some cases, NICE will recommend that the cancer drug is funded through the CDF, which enables further evaluation of its place in therapy. Drugs that have a European Union (EU) or United Kingdom marketing authorisation for radioiodine refractory differentiated thyroid cancer will therefore be reviewed under this process and if found to be clinically and cost effective will become established treatment within the National Health Service.

The UK remains a member of the EU until Article 50 negotiations have concluded. EU law continues to apply and ongoing compliance with EU law is considered important in facilitating orderly transition, for negotiating purposes, and to offer certainty in the meantime. As long as the UK is subject to EU law, the present arrangements remain in place.